UroGen Pharma Ltd. (URGN) — Analyst outlook / Analyst consensus target is. Based on 15 analyst ratings, the consensus is bullish — 11 Buy, 4 Hold.
The consensus price target is $35.60 (low: $16.00, high: $60.00), representing an upside of 65.5% from the current price $21.51.
Analysts estimate Earnings Per Share (EPS) of $-3.13 and revenue of $0.09B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.96 vs est $-3.13 (beat +5.4%). 2025: actual $-3.19 vs est $-3.20 (beat +0.2%). Analyst accuracy: 97%.
URGN Stock — 12-Month Price Forecast
$35.60
▲ +65.50% Upside
Average Price Target
Based on 15 Wall Street analysts offering 12-month price targets for UroGen Pharma Ltd., the average price target is $35.60, with a high forecast of $60.00, and a low forecast of $16.00.
The average price target represents a +65.50% change from the last price of $21.51.
Highest Price Target
$60.00
Average Price Target
$35.60
Lowest Price Target
$16.00
URGN Analyst Ratings
Buy
Based on 15 analysts giving stock ratings to UroGen Pharma Ltd. in the past 3 months
EPS Estimates — URGN
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.96
vs Est –$3.13
▲ 5.7% off
2025
Actual –$3.19
vs Est –$3.20
▲ 0.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — URGN
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.090B
vs Est $0.091B
▼ 0.7% off
2025
Actual $0.110B
vs Est $0.112B
▼ 1.9% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
